Genmab stock surges 11% on positive cancer drug trial data

What happened: Genmab A/S (NASDAQ:GMAB) shares rose 11% Monday after positive topline Phase 3 results for epcoritamab plus R-CHOP in newly diagnosed diffuse large B-cell lymphoma. Key numbers: 11% share rise. 51% reduction in risk of disease progression or death, hazard ratio 0.49. Why it matters: The EPCORE DLBCL-2 trial, run with AbbVie (NYSE:ABBV), is the first Phase 3 study of a bispecific antibody combination to show this improvement in frontline DLBCL. The companies will engage global regulators on next steps.

Genmab A/S (NASDAQ:GMAB) shares rose 11% Monday after positive topline Phase 3 results for epcoritamab plus R-CHOP in newly diagnosed diffuse large B-cell lymphoma.

The EPCORE DLBCL-2 trial, run with AbbVie (NYSE:ABBV), is the first Phase 3 study of a bispecific antibody combination to show this improvement in frontline DLBCL. The companies will engage global regulators on next steps.